ASO Visual Abstract: KRAS and TP53 Circulating Tumor DNA are Prognostic in Localized Pancreatic Cancer

Krishay Sridalla Dominic J. Vitello Madison Cox Larissa Masnyk Amy Wells A. Horowitz Dhavan Shah J. Machhi Vishvetha Rengaraju Anastasia Chibucos Claire Shen Lauren M. Janczewski John Abad Kevin Dawravoo David J. Bentrem L. J. Jennings Qiang Zhang Akhil Chawla

Sep 2026 · Annals of Surgical Oncology · Vol 33, pp. 10175 - 10176 · 0 citations · 1 references

Medicine

TL;DR

Findings support next-generation sequencing-based ctDNA as a prognostic biomarker to refine risk stratification in patients undergoing neoadjuvant therapy.

DOI PubMed Semantic Scholar

View source

Similar papers

Sep 2026

Beyond Major Pathologic Response in Lung Cancer: Biomarkers Predict Outcomes.

Neoadjuvant chemoimmunotherapy improves outcomes in resectable non-small cell lung cancer, yet pathologic response incompletely predicts durability of benefit. Spatial profiling using resected tumors and lymph nodes revealed distinct immune subtypes and identified a gene signature associated with improved outcomes, pro...

V. Wang, Natalie M. Ward, J. Kratz · Clinical Cancer Research · 0 citations

Sep 2026

Molecular residual disease: Charting a new path for treating resectable solid tumors.

Molecular residual disease (MRD), detected via circulating tumor DNA (ctDNA) after curative-intent surgery, identifies resectable solid tumor patients at high recurrence risk, thereby enabling enriched trials with larger effect sizes and smaller samples. Yet enrichment narrows the eligible population and thus challenge...

S. Kobayashi, T. Hashimoto, H. Bando et al. · Cancer Cell · 0 citations

Open access Oct 2026

Correction: Kühn et al. HPV Status as Prognostic Biomarker in Head and Neck Cancer—Which Method Fits the Best for Outcome Prediction? Cancers 2021, 13, 4730

There was an error in the original publication [...].

J. Kühn, W. Schmid, Sandrina Körner et al. · Cancers · 0 citations

Open access Sep 2026

Prognostic Markers in Meningioma: Effectiveness of FISH‐Assessed CDKN2A/B Homozygous Deletion and Limits of Surrogate p16/MTAP Immunohistochemistry in Predicting Disease‐Specific Survival

This study evaluated multiple CDKN2A/B FISH cutoffs and assessed the diagnostic and prognostic performance of MTAP and p16 IHC.

A. Ricci, Filippo Nozzoli, Alessandro Biale et al. · Neuropathology and Applied N... · 0 citations

Open access Sep 2026

Prognostic Value and Longitudinal Dynamics of Multigene Circulating Tumor DNA in Advanced Pancreatic Cancer Treated with 5-Fluorouracil-Based Chemotherapy

It is suggested that baseline and early on-treatment multigene ctDNA carries prognostic information in advanced PDAC, although superiority over KRAS or CA19-9 was not established.

Gi-Ye-On Lee, J. W. Chun, Dong-eun Lee et al. · International Journal of Mol... · 0 citations

Editorial Sep 2026

Challenges of Using Circulating Tumour DNA: Insights from Advanced Prostate Cancer.

Precision oncology relies on integrating tumour fraction, variant allele frequency, clonal haematopoiesis of indeterminate potential assessment, pathogenicity, and clinical context into next-generation sequencing interpretation, enabling biologically informed and clinically meaningful treatment decisions while reducing...

T. Taha, Ossian Longoria, J. de Bono · European Urology · 0 citations